



## **Adherium Commences Production and US Market Release of Advanced Teva pMDI Compatible Smartinhaler**

**Melbourne, Australia – 04 December 2023:** Adherium Limited (ASX: ADR), a leader in digital health technologies, is pleased to announce it has commenced production and market release of its advanced Hailie® Smartinhaler® connecting Teva Pharmaceutical Industries Ltd. (Teva) available authorized generic option of ProAir® HFA Albuterol Sulphate pressurised metered dose inhalers (pMDIs) with its new, next generation sensor capturing physiological data such as inhalation flow rate.

This advanced digital sensor further supports respiratory-focused hospitals, medical groups and payors to actively manage respiratory disease for improved health outcomes, enabling reimbursement, and saving healthcare costs through remote patient monitoring.

Adherium is currently working with its initial large scale strategic partners, Allergy Partners and SENTA, to enroll patients on its Hailie platform using its range of US FDA 510(k) cleared Smartinhalers to generate and transmit the data enabling remote patient monitoring reimbursement. The production and sale of the Hailie platform underpins Adherium reaching a cash flow positive position.

Now achieving four market release milestones of the next generation Hailie Smartinhalers, Adherium progressed on its commercial strategy to 79% market coverage for sensors capturing physiological data such as inhalation flow rate, and 91% market coverage for adherence tracking of US top 20 branded inhaler medications by sales volume. Hailie Smartinhalers are the only FDA 510(k) cleared drug agnostic sensor available today to offer physiological data insights on inhaler technique.

Francis White, Vice President of Global Business Development at Adherium, states: *“We are pleased to be able to provide access to Hailie Smartinhalers to tens of thousands of patients through our growing partnerships with US respiratory hospital and medical group systems, equipping patients with the most advanced tools to manage their respiratory health and vastly improve their quality of life.”*

For further information, please visit [www.adherium.com](http://www.adherium.com) and [www.hailie.com](http://www.hailie.com).

**-ENDS-**

This ASX announcement was approved and authorised for release by the Board of Adherium.

Enquiries:

Rick Legleiter

CEO, Adherium Limited

[investors@adherium.com](mailto:investors@adherium.com)

### **About Adherium**

Adherium Limited (ASX: ADR) is a digital health company providing solutions for improving patient treatment with remote monitoring and data solutions. Its Hailie® system is transforming management of chronic respiratory conditions, especially asthma and chronic obstructive pulmonary disease. Hailie improves patient health through better adherence and self-management while enabling doctors to be paid for remote work and saving costs across health systems by avoiding hospital admissions. Adherium's clinically proven sensors, app and powerful data platform provide remote, real-time, personalised information to patients and clinicians. Adherium is increasing sales in US and other markets by pursuing partnerships with major hospital systems, medical groups and insurers. For more information, visit <https://www.adherium.com/>

### **About the Hailie Platform**

Adherium's proprietary Hailie® platform is transforming the management of chronic respiratory conditions including asthma and chronic obstructive pulmonary disease. Hailie's cloud-based platform captures and shares information from Bluetooth enabled sensors that wrap around a patient's prescribed inhaler. With a user-friendly app, a patient can receive, act on and share their personal information and data reports with doctors and carers.

Hailie's growing portfolio of sensors have been cleared by the FDA and approved by the TGA, EU and UK. The clinically proven sensors remotely capture when and how an inhaler is being used through key physiological parameters including inhalation flow rate, anywhere people live, work and study.

The Hailie solution creates and delivers data supporting far better patient medication adherence, behavioural influencing, escalations and interventions to improve health outcomes and self-management by patients. The Hailie platform drives health costs down by reducing hospital admissions and enables doctors to bill for remote patient management.

Independent studies show the Hailie platform increases medication adherence by 180% in children with an associated 80% reduction in hospital admissions. Hailie has been shown to increase adherence by 59% in adults with a reduction in severe exacerbations of 61%.